The impact of type 2 diabetes mellitus on the clinical profile, myocardial fibrosis, and prognosis in non-ischemic dilated cardiomyopathy: a prospective cohort study
Authors' conclusion
Patients with T2DM represented a more severe clinical profile and experienced more adverse outcomes compared to those without T2DM in a large DCM cohort.
Study context
- Population
- Patients with non-ischemic dilated cardiomyopathy (DCM), enrolled June 2012 to October 2021Propensity score matching (PSM) cohort 438
- Participants
- 1,152 patients
- Exposure
- T2D vs non-T2D in non-ischemic DCM
- T2DMn = 155
- Outcome
- All-cause mortality and heart transplantation
- Follow-up
- Median 38 months (IQR 20-57 months)
Methodological detailspropensity-score matched analysis
- Propensity-score matched analysis
Main finding
As reported in the abstract
median 38 months
T2DM vs non-T2DMHazard ratio (95% CI)P value
Overall cohort
1.61(1.13–2.33)
P = 0.01PSM cohort
1.54(1.05–2.24)
P = 0.02- Patients reaching primary endpoint
- 239
Observational data: associations, not effects.
Further findings
Age · baseline
P < 0.001
Hypertension · baseline
P < 0.001
AF · baseline
P < 0.001
LGE presence · baseline
P = 0.02
LV ejection fraction · baseline
P < 0.001
Extracellular volume fraction (ECV) · baseline
P = 0.01
Native T1 · baseline
P = 0.01
- Higher New York Heart Association (NYHA) functional class with T2DM · baseline
- P = 0.003
- Cause-specific death · HF death: higher risk with T2DM
- P = 0.006
- Cause-specific death · non-cardiac death: higher risk with T2DM
- P = 0.02
- Cause-specific death · sudden cardiac death: not associated
- P = 0.16
Original publication
The impact of type 2 diabetes mellitus on the clinical profile, myocardial fibrosis, and prognosis in non-ischemic dilated cardiomyopathy: a prospective cohort study. Cardiovasc Diabetol. Published 1 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →